Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 675 of 885 entries
View as:

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT04119050 Org: User:
Start: 08/15/19 End: 04/10/28 Due: 04/10/29

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05076877 Org: User:
Start: 09/17/21 End: 02/10/22 Due: 02/10/23

A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device

Phase: N/A Priority: Normal
NCT ID: NCT02060929 Org: User:
Start: 10/31/13 End: 01/31/14 Due: 01/31/15

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03468777 Org: User:
Start: 03/06/18 End: 07/09/18 Due: 07/09/19

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT01965613 Org: User:
Start: 01/31/14 End: 12/31/16 Due: 12/31/17

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02743546 Org: User:
Start: 07/20/16 End: 03/31/20 Due: 03/31/21

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Phase: N/A Priority: Normal
NCT ID: NCT03955913 Org: User:
Start: 08/01/19 End: 09/19/22 Due: 09/19/23

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02703272 Org: User:
Start: 07/01/16 End: 06/11/21 Due: 06/11/22

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04791319 Org: User:
Start: 05/03/21 End: 03/31/22 Due: 03/31/23

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03523442 Org: User:
Start: 08/31/18 End: 12/31/25 Due: 12/31/26

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Phase: N/A Priority: Normal
NCT ID: NCT04936308 Org: User:
Start: 09/28/21 End: 07/16/26 Due: 07/16/27

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06425991 Org: User:
Start: 06/07/24 End: 02/28/27 Due: 02/28/28

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Phase: N/A Priority: Normal
NCT ID: NCT04794101 Org: User:
Start: 12/04/20 End: 12/19/29 Due: 12/19/30

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05272150 Org: User:
Start: 07/13/22 End: 05/21/25 Due: 05/21/26

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT05444530 Org: User:
Start: 07/21/22 End: 10/10/25 Due: 10/10/26

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06143878 Org: User:
Start: 02/01/24 End: 06/01/27 Due: 06/01/28

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Phase: N/A Priority: Normal
NCT ID: NCT06211764 Org: User:
Start: 04/09/24 End: 04/14/31 Due: 04/14/32

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05552222 Org: User:
Start: 10/25/22 End: 10/28/33 Due: 10/28/34

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06385080 Org: User:
Start: 04/22/24 End: 04/17/28 Due: 04/17/29

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02617758 Org: User:
Start: 11/30/15 End: 06/30/16 Due: 06/30/17

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01767948 Org: User:
Start: 12/31/12 End: 11/30/13 Due: 11/30/14

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT03080987 Org: User:
Start: 06/27/17 End: 06/25/18 Due: 06/25/19

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04487080 Org: User:
Start: 09/30/20 End: 06/29/27 Due: 06/29/28

A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics

Phase: N/A Priority: Normal
NCT ID: NCT01607762 Org: User:
Start: 02/29/12 End: 10/31/12 Due: 10/31/13

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02421185 Org: User:
Start: 05/25/15 End: 05/16/19 Due: 05/16/20